Bioventix Announces Patent Opposition

Bioventix plc                                 

                        ("Bioventix" or the "Company")                         

                     Bioventix Announces Patent Opposition                     

It has come to the Company's attention that DiaSource ImmunoAssays S.A. of
Belgium ("DiaSource") has recently been granted a European patent in the field
of anti vitamin D antibodies and their use in assays (i.e. tests) for vitamin D
sufficiency and deficiency.

After having taken legal and patent advice from the Company's advisors, the
Company is taking action to vigorously oppose this particular patent granted to
DiaSource.

Peter Harrison, CEO of Bioventix plc said "We are vigilant in monitoring patent
property that could potentially impact on our business and this patent relating
to anti-vitamin D antibodies is relevant to us. After having taken advice from
our patent agents and patent lawyers on the strength of our position, we have
taken the decision to commence formal proceedings directed towards the validity
of certain claims in this patent."

For further information please contact:

Bioventix plc          Chief Executive Officer Tel: [phone]              
                                                                               
Peter Harrison                                                                 
                                                                               
finnCap Ltd            Corporate Finance       Tel: [phone]              
                                                                               
Geoff Nash/Simon Hicks Corporate Broking                                       
                                                                               
Steve Norcross                                                                 

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce a
suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on ISDX under the symbol BVXP.